Boston Scientific Corp. (NYSE: BSX) announced it has won U.S. Food and Drug Administration approval for a defibrillator which is implanted just under the skin and does not require wires, called leads, that connect to the heart. Investors lifted the Natick, Mass. medical device company’s stock more than 2 percent on the news.
BSX wins FDA approval for wireless defibrillator
Thu, 10/04/2012 - 12:00am